Long intergenic non-protein coding RNA 1527 (LINC01527)

Long intergenic non-protein coding RNA 1527 (LINC01527) is a long non-coding RNA (lncRNA) gene that does not encode a protein but is transcribed into a functional RNA molecule[1][5]. LINC01527 is classified as a long intergenic non-coding RNA, meaning it is typically located between protein-coding genes and does not overlap with them[1][5][7]. LINC01527 has been identified as a component of multi-lncRNA prognostic signatures for cancer, particularly as part of a 22-lncRNA risk signature that can stratify melanoma patients into low- and high-risk groups based on expression levels[3]. High expression of LINC01527 correlates with better prognosis in melanoma, and its expression is associated with T stage and patient age in this disease[3]. There is also evidence that LINC01527 is differentially expressed between tumor and normal lung tissue, and it has been reported as downregulated in pathologic samples in some lung cancer studies[2]. Its primary recognized functions include gene regulation at the RNA level, contributing to gene expression networks, and acting as a biomarker for cancer prognosis rather than as a direct therapeutic target or enzyme/receptor[3][7]. LINC01527 has no known direct interactions with approved drugs, and there is no evidence it serves as a therapeutic target for small molecules or biologic agents. However, as an RNA biomarker, it may be useful for future patient selection or disease risk stratification in oncology, but further study and clinical validation are required[3]. No notable safety concerns, contraindications, or therapeutic challenges are reported, consistent with its role as a biomarker rather than an actionable drug target.

Other names

lnc-SPRR2D-1RP1-13P20.6LINC01527